CHA Vaccine Research Institute (KOSDAQ:261780)
South Korea · Delayed Price · Currency is KRW 2,780.00
-50.00 (-1.77%)
At close: Oct 28, 2025
CHA Vaccine Research Institute Company Description
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases.
Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster.
The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer vaccine. Cha Vaccine Research Institute Co., Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
CHA Vaccine Research Institute
| Country | South Korea |
| Founded | 2000 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Jungsun Yum |
Contact Details
Address: 560 Dunchon-daero Seongnam, 13230 South Korea | |
| Phone | 82 31 737 8208 |
| Website | chavaccine.com |
Stock Details
| Ticker Symbol | 261780 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jungsun Yum | Chief Executive Officer |